Company: BIVIW
Filing Date: 2025-09-25
Form Type: DEF 14A
Source: 0001520138-25-000287
Chunk: 15

Company: BIOVIE INC.
Filing Date: 2025-09-25
Form: DEF 14A
Chunk 15
---
 Ionis Pharmaceuticals from 2018 to 2021. In addition, Mr. Farag spent over 16 years at Amgen Inc. in a variety of finance and operational
roles including Chief Financial Officer of Amgen's Intercontinental Region from 2013 to 2018 and as its Head of International FP&A
and Interim International Chief Financial Officer from 2009 to 2013. Mr. Farag holds a BA from the University of California, Santa Barbara.

Mr. Farag’s qualifications to serve on our Board of Directors are
primarily based on his experience as a biotech and global finance executive with a track record of scaling companies through transformational
growth.

Mr. Sigmund Rogich has served as a director of the Company since
2020. He is the CEO and President of The Rogich Communications Group and serves on the Board of Keep Memory Alive, a philanthropic organization
which raises awareness about brain disorders and Alzheimer’s disease. Keep Memory Alive funds clinical trials to advance new treatments
for patients with Alzheimer’s, Huntington’s and Parkinson’s disease, as well as multiple sclerosis. Mr. Rogich was formerly
the U.S. Ambassador to Iceland. He has served as a senior consultant to Presidents Ronald Reagan and George H.W. Bush. Mr. Rogich serves
on multiple boards of directors for charitable causes.

Mr. Rogich’s qualifications to serve on our Board of Directors are
based on his experience in the Communications sector and philanthropic organization raising awareness about brain disorders. His experience
in service as a senior consultant to candidates of the highest office.

Mr. Michael Shermanhas served as a director of the Company since
2017. He retired from his position as a Managing Director at Barclays Plc in 2018, where he had worked since 2008. Previously he was a
Managing Director at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant experience in
healthcare finance, most recently assisting on a $450 million convertible transaction for Neurocrine Biosciences. He has worked on successful
financial transactions for Teva Pharmaceutical Industries, Amgen Inc., Cubist Pharmaceuticals, Merck & Co., and Cardinal Health, among
other companies. After graduating from the University of Pennsylvania, Michael Sherman received his JD, cum laude, from the Harvard Law
School.

| -9- |

Mr. Sherman’s qualifications to serve on our Board of Directors are
primarily based on his decades of finance